Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

British Journal of Cancer

Volumn 98, Issue 10, 2008, Pages 1608-1613

  Paz Ares, L ^a   Ross, H ^b   O'Brien, M ^c   Riviere, A ^d   Gatzemeier, U ^e   Von Pawel, J ^f   Kaukel, E ^g   Freitag, L ^h   Digel, W ⁱ   Bischoff, H ^j   Garcia Campelo R ^k   Iannotti, N ^l   Reiterer, P ^m   Bover, I ⁿ   Prendiville, J ^o   Eisenfeld, A J ^p   Oldham, F B ^p   Bandstra, B ^p   Singer, J W ^p   Bonomi, P ^q  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e KRANKENHAUS GROSSHANSDORF   (Germany)

^f ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^g Asklepios Klinik Harburg   (Germany)

^h LUNGENKLINIK HEMER   (Germany)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k Juan Canalejo Materno Infantil Hospital   (Spain)

^l Hem Onc Associates of the Treasure Coast   (United States)

^m Masarykovy Nemocnice   (Czech Republic)

ⁿ HOSPITAL SON LLÀTZER   (Spain)

^o GUY S HOSPITAL   (United Kingdom)

^p Cell Therapeutics Inc   (United States)

^q RUSH UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Docetaxel; Lung cancer; Poliglumex

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CIMETIDINE; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL POLIGLUMEX; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAZARD RATIO; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PATIENT SELECTION; POLYGLUTAMIC ACID; QUALITY OF LIFE; TAXOIDS; TREATMENT OUTCOME;

EID: 43649092756     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604372     Document Type: Article

References (19)

1. Bernareggi A, Oldham F, Baker B, Besman M, Singer JW (2005) XYOTAX (paclitaxel poliglumex, PPX): tumor accumulation and prolonged exposure to paclitaxel. Presented at The 11th World Congress on Lung Cancer, July 3-6, Barcelona, Spain
2. Boddy AV, Plummer ER, Todd R, Sludden J, Griffin M, Robson L, Cassidy J, Bissett D, Bernareggi A, Verrill MW, Calvert AH (2005) A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 11(21): 7834-7840
3. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18: 2354-2362
4. Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H (2003) Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 42: 1089-1105
5. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn Jr PA (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597
6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66
7. C, Newman RA, Wu QP, Ke S, Chen W, Hutto T, Kan Z, Brannan MD, Charnsangavej C, Wallace S (2000) Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol 46: 416-422
8. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392
9. O'Brien MER, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynskyi BT, Ganul VL, Hotko YS, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW. Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC). J Thoracic Oncol (in press
10. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker Jr S, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353
11. Podgorski I, Sloane BF (2003) Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp 70: 263-276
12. Richards DA, Richards P, Bodkin D, Neubauer MA, Oldham F (2005) Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study. Clin Lung Cancer 7: 215-220
13. Ross H, Bonomi P, Langer C, O'Brien M, O'Byrne K, Paz-Ares L, Sandler A, Socinski M, Oldham F, Singer J (2006) Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2). J Clin Oncol 24: 7039
14. Rothmann M, Li N, Chen G, Chi GY, Temple R, Tsou HH (2003) Design and analysis of non-inferiority mortality trials in oncology. Stat Med 22: 239-264
15. Shaffer SA, Baker-Lee C, Kennedy J, Lai MS, de Vries P, Buhler K, Singer JW, Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2007) In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother Pharmacol 59: 537-548
16. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabá, Seymour L, National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132
18. Singer JW, Shaffer S, Baker B, Bernareggi A, Stromatt S, Nienstedt D, Besman M (2005) Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs 16: 243-254
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216